The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000153617

Enrollment

Registered

2005-08-15

Start date

2005-12-11

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The use of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi. Dipyridamole is used to enhance the uptake of Tc99m-Sestamibi in repeat parathyroid imaging.

Study design

Allocation

Non-randomised trial

Intervention model

Crossover

Primary purpose

Diagnosis

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Previous negative 99mTc Sestamibi parathyroid scan. No subsequent parathyroid surgery. Abnormal parathyroid Hormone (PTH ) levels. Strong clinical suspicion of parathyroid adenoma. Permission of referring doctor. Informed consent of patient.

Exclusion criteria

Age younger than 18 years, pregnancy, unable to gain informed consent, unstable cardiac disease, Asthma, hypotension, hypersensitivity to aspirin or dipyridamole.

Outcome results